Wynona Coles

3.5k total citations · 1 hit paper
28 papers, 2.5k citations indexed

About

Wynona Coles is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Wynona Coles has authored 28 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Genetics, 18 papers in Hematology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Wynona Coles's work include Hemoglobinopathies and Related Disorders (27 papers), Iron Metabolism and Disorders (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). Wynona Coles is often cited by papers focused on Hemoglobinopathies and Related Disorders (27 papers), Iron Metabolism and Disorders (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). Wynona Coles collaborates with scholars based in United States, Malaysia and United Kingdom. Wynona Coles's co-authors include Mark T. Gladwin, Vandana Sachdev, Lori A. Hunter, William C. Blackwelder, Oswaldo Castro, Griffin P. Rodgers, Inez Ernst, Alan N. Schechter, Frederick P. Ognibene and James S. Nichols and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Wynona Coles

26 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease

2004 916 citations Mark T. Gladwin, Vandana Sachdev et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Wynona Coles

Since Specialization

Citations

This map shows the geographic impact of Wynona Coles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wynona Coles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wynona Coles more than expected).

Fields of papers citing papers by Wynona Coles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wynona Coles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wynona Coles. The network helps show where Wynona Coles may publish in the future.

Co-authorship network of co-authors of Wynona Coles

This figure shows the co-authorship network connecting the top 25 collaborators of Wynona Coles. A scholar is included among the top collaborators of Wynona Coles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wynona Coles. Wynona Coles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell Disease 2025 ·Transplantation and Cellular Therapy ·(unknown), Neal Jeffries, Mary Link, Wynona Coles, P Pollack, (unknown), (unknown), Elizabeth Harvey, (unknown), (unknown), John F. Tisdale, Matthew M. Hsieh	1
2	A machine learning‐based workflow for predicting transplant outcomes in patients with sickle cell disease 2024 ·British Journal of Haematology ·Haiou Li, Vandana Sachdev, Xin Tian, (unknown), Matthew M. Hsieh, Courtney D. Fitzhugh, (unknown), Wynona Coles, (unknown), Anna Conrey, Colin O. Wu, Swee Lay Thein	1
3	Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism 2022 ·Blood ·(unknown), Devdeep Mukherjee, (unknown), Wynona Coles, Matthew M. Hsieh, Laura W. Dillon, Christopher S. Hourigan, Courtney D. Fitzhugh	22
4	Reversal of pre-capillary pulmonary hypertension in a patient with sickle cell anemia who underwent haploidentical peripheral blood stem cell transplantation 2017 ·Bone Marrow Transplantation ·C. Pittman, Matthew M. Hsieh, Wynona Coles, John F. Tisdale, Nargues Weir, Courtney D. Fitzhugh	19
5	At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT 2017 ·Blood ·Courtney D. Fitzhugh, Stefan Cordes, Tiffani Taylor, Wynona Coles, (unknown), Mary Link, Matthew M. Hsieh, John F. Tisdale	112
6	Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT 2017 ·Blood Advances ·Courtney D. Fitzhugh, Matthew M. Hsieh, Tiffani Taylor, Wynona Coles, (unknown), (unknown), Elizabeth C. Wright, Neal Jeffries, Christopher Gamper, Jonathan D. Powell, Leo Luznik, John F. Tisdale	70
7	At Least 20% Donor Myeloid Chimerism Is Necessary to Reverse the Sickle Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation 2016 ·Blood ·Courtney D. Fitzhugh, Matthew M. Hsieh, Stefan Cordes, Tiffani Taylor, Wynona Coles, (unknown), John F. Tisdale	3
8	Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia 2015 ·PLoS ONE ·Courtney D. Fitzhugh, Matthew M. Hsieh, Darlene Allen, Wynona Coles, Cassie Seamon, Michael Ring, Xiongce Zhao, Caterina P. Minniti, Griffin P. Rodgers, Alan N. Schechter, John F. Tisdale, James G. Taylor	39
9	Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype 2014 ·JAMA ·Matthew M. Hsieh, Courtney D. Fitzhugh, R. Patrick Weitzel, Mary E. Link, Wynona Coles, Xiongce Zhao, Griffin P. Rodgers, Jonathan D. Powell, John F. Tisdale	233
10	Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Severe Sickle Cell Disease (SCD) 2011 ·Blood ·Matthew M. Hsieh, Courtney D. Fitzhugh, R. Patrick Weitzel, Wynona Coles, Mary Link, John F. Tisdale	2
11	Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease 2009 ·British Journal of Haematology ·Caterina P. Minniti, Roberto F. Machado, Wynona Coles, Vandana Sachdev, Mark T. Gladwin, Gregory J. Kato	56
12	Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension 2007 ·American Journal of Respiratory and Critical Care Medicine ·Anastasia Anthi, Roberto F. Machado, Maria Jison, Angelo M. Taveira‐DaSilva, Lewis J. Rubin, Lori A. Hunter, Christian J. Hunter, Wynona Coles, James Nichols, Nilo A. Avila, Vandana Sachdev, Clara C. Chen, Mark T. Gladwin	194
13	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients With Sickle Cell Disease 2007 ·Journal of the American College of Cardiology ·Vandana Sachdev, Roberto F. Machado, Yukitaka Shizukuda, (unknown), Stanislav Sidenko, Inez Ernst, (unknown), Wynona Coles, Douglas R. Rosing, William C. Blackwelder, Oswaldo Castro, Gregory J. Kato, Mark T. Gladwin	212
14	Severity of pulmonary hypertension during vaso‐occlusive pain crisis and exercise in patients with sickle cell disease 2006 ·British Journal of Haematology ·Roberto F. Machado, A. Kyle Mack, Sabrina Martyr, Christopher F. Barnett, Peter H. MacArthur, Vandana Sachdev, Inez Ernst, Lori A. Hunter, Wynona Coles, James Nichols, Gregory J. Kato, Mark T. Gladwin	83
15	Levels of soluble endothelium‐derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality 2005 ·British Journal of Haematology ·Gregory J. Kato, Sabrina Martyr, William C. Blackwelder, James S. Nichols, Wynona Coles, Lori A. Hunter, Marie‐Luise Brennan, Stanley L. Hazen, Mark T. Gladwin	162
16	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients with Sickle Cell Disease. 2005 ·Blood ·Vandana Sachdev, Roberto F. Machado, (unknown), (unknown), Stanislav Sidenko, Inez Ernst, (unknown), Wynona Coles, (unknown), William C. Blackwelder, Oswaldo Castro, Gregory J. Kato, Mark T. Gladwin	1
17	Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension 2005 ·British Journal of Haematology ·Roberto F. Machado, Sabrina Martyr, Gregory J. Kato, Robyn J. Barst, Anastasia Anthi, M. Robinson, Lori A. Hunter, Wynona Coles, (unknown), Christian J. Hunter, Vandana Sachdev, Oswaldo Castro, Mark T. Gladwin	161
18	Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease breakdown → 2004 ·New England Journal of Medicine ·Mark T. Gladwin, Vandana Sachdev, Maria Jison, Yukitaka Shizukuda, Jonathan F. Plehn, (unknown), (unknown), Wynona Coles, James S. Nichols, Inez Ernst, Lori A. Hunter, William C. Blackwelder, Alan N. Schechter, Griffin P. Rodgers, Oswaldo Castro, Frederick P. Ognibene	916
19	Acute on Chronic Pulmonary Hypertension in Patients with Sickle Cell Disease. 2004 ·Blood ·Gregory J. Kato, Sabrina Martyr, Roberto F. Machado, Vandana Sachdev, Inez Ernst, Lori A. Hunter, Wynona Coles, (unknown), Christian J. Hunter, Mark T. Gladwin	6
20	Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy. 2004 ·Blood ·Roberto F. Machado, Sabrina Martyr, Anastasia Anthi, Gregory J. Kato, Lori A. Hunter, Wynona Coles, James S. Nichols, Oswaldo Castro, Mark T. Gladwin	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact